KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Income from Continuing Operations (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Income from Continuing Operations for 18 consecutive years, with 727200000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 10.08% year-over-year to 727200000.0; the TTM value through Mar 2026 reached 4423400000.0, down 1.69%, while the annual FY2025 figure was 4504900000.0, 2.09% up from the prior year.
  • Income from Continuing Operations hit 727200000.0 in Q1 2026 for Regeneron Pharmaceuticals, down from 844600000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1460000000.0 in Q3 2025 and bottomed at 722000000.0 in Q1 2024.
  • Average Income from Continuing Operations over 5 years is 1055100000.0, with a median of 973500000.0 recorded in 2022.
  • Year-over-year, Income from Continuing Operations tumbled 72.5% in 2022 and then skyrocketed 47.9% in 2024.
  • Regeneron Pharmaceuticals' Income from Continuing Operations stood at 1197100000.0 in 2022, then decreased by 3.13% to 1159600000.0 in 2023, then fell by 20.86% to 917700000.0 in 2024, then decreased by 7.97% to 844600000.0 in 2025, then decreased by 13.9% to 727200000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 727200000.0, 844600000.0, and 1460000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.